Esco Technologies Inc: Novel Bioprocessing Strategies for Cell/Gene Therapy and Biomedical Engineering

Esco Technologies Inc: Novel Bioprocessing Strategies for Cell/Gene Therapy and Biomedical Engineering

04/02/2019, 3:15 PM - 4:00 PM

Javits Conventions Center - INNOPHEX Stage - Booth 3941
Language:
English
In the cell and gene therapy modality there is often a debate on scaling up versus scaling out. Whilst there are multiple multi layered culture ware with automated cell harvesting and usage of microcarriers there is an unmet need in the market for linearly scalable platforms for adherent cell culture with minimal downstream processing costs. Esco Aster has commercialized a patented adherent Tide Motion platform for the highest yield lowest cost, single use linearly scalable with consistent quality and minimal batch to batch variation with patented closed cell harvesting. This has the highest kla and otr across various bioprocessing platforms and achieved a cogs of $20 per million stem cells for Mesenchymal stem cells and is linearly scalable up to 1e12 cells sufficient for allogeneic stem cell therapy. Other adherent cell lines for expansion of iPSCs and hESCs or viral vectors will be discussed as well during the talk. In the cell and gene therapy modality there is often a debate on scaling up versus scaling out. Whilst there are multiple multi layered culture ware with automated cell harvesting and usage of microcarriers there is an unmet need in the market for linearly scalable platforms for adherent cell culture with minimal downstream processing costs. Esco Aster has commercialized a patented adherent Tide Motion platform for the highest yield lowest cost, single use linearly scalable with consistent quality and minimal batch to batch variation with patented closed cell harvesting. This has the highest kla and otr across various bioprocessing platforms and achieved a cogs of $20 per million stem cells for Mesenchymal stem cells and is linearly scalable up to 1e12 cells sufficient for allogeneic stem cell therapy. Other adherent cell lines for expansion of iPSCs and hESCs or viral vectors will be discussed as well during the talk.

Contributors

  • Xiangliang Lin

    Speaker

    CEO

    Esco Aster Pte Ltd.

    XL Lin graduated with a Bachelor of Sciences from the University of Sydney, joining the family business upon graduating. He started the Esco Group of...

Type of Session

  1. Type of Session
    Session

Categories

  1. Track
    INNOPHEX

We use cookies to operate this website and to improve its usability. Full details of what cookies are, why we use them and how you can manage them can be found by reading our Privacy & Cookies page. Please note that by using this site you are consenting to the use of cookies.